Pharmaceutical Executive-09-01-2021

Doubling Down On Innovation, Recovery

September 14, 2021

Features

41

9

Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.

Serial Problem Solver

September 14, 2021

Executive Profile

41

9

Teva CEO Kåre Schultz talks about his long industry experience tackling major strategic and operational challenges, and how he is progressing on his current mission to turn around Teva’s fortunes.